Division of Pfizer Inc.
Latest From Medivation Inc.
AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.
Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?
Pfizer's third quarter earnings call covered a lot of ground, from pipeline updates, management's latest thinking on M&A, and strategic options for consumer healthcare, to industry trends like Amazon entering the drug distribution arena.
Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
David T Hung, MD, Pres. & CEO
Jennifer Jarrett, CFO
Joseph Lobacki, Chief Commercial Officer
Marion McCourt, COO
- Contact Info
Phone: (415) 543-3470
525 Market St.
San Francisco, CA 94105
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.